Western blot analysis showed, in LFs derived from patients with BOS, a 50% reduction in the activity of cAbl with both LIP‐Im and LIP‐HA44700‐Im, after 24 h of treatment. The gene discussed is ABL1; the disease is Buschke-Ollendorff syndrome.